MLD and Laval University collaborators publish key Parkinson's disease plasmalogen paper

MLD is pleased to announce that its paper “Neuroprotection and immunomodulation in the gut of parkinsonian mice with a plasmalogen precursor” was recently published in Brain Research.  This work was performed in collaboration with Dr. Soulet and Dr. Di Paolo from Laval University. The publication describes the ability of MLD’s plasmalogen precursor PPI-1011 to not only protect plasmalogen levels, but also prevent the loss of dopaminergic neurons in the gut of MPTP-treated mice, a commonly used model of Parkinson’s disease.  In addition, PPI-1011 reduced gut inflammation by reducing infiltration of activated macrophages. Interestingly, the protective effects of PPI-1011 were observed whether treatment occurred pre- or post-MPTP administration.  The results suggest that PPI-1011 has neuroprotective and anti-inflammatory properties and expands on our previous data illustrating the neuroprotective effects of PPI-1011 in the brain of MPTP-treated mice. The findings further support the potential utility of PPI-1011 for the treatment of both early and advanced Parkinson’s disease.     

Pubmed link - https://www.ncbi.nlm.nih.gov/pubmed/31525350

Sciencedirect link - https://doi.org/10.1016/j.brainres.2019.146460